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Antisera against a partially purified growth hormone 
receptor derived from rabbit liver were generated in 
guinea pigs. The antisera specifically inhibited the 
binding of ‘261-ovine growth hormone (oGH) to liver 
membranes but had no effect on the binding of lz51- 
ovine prolactin to rabbit mammary gland receptors. 
These antisera did not bind or destroy ‘251-oGH. More- 
over, the binding of labeled growth hormone to mem- 
brane particles derived from liver of several species 
was also inhibited by the antisera, thus suggesting that 
immunological determinants of the growth hormone 
receptor of several species are similar. y-Globulin frac- 
tions derived from the antisera were responsible for 
the inhibition. In addition ‘251-y-globulin derived from 
one antiserum bound to membrane pellets with a cor- 
responding decline in ‘251-oGH binding. Kinetic analysis 
of inhibition of 12’I-oGH binding suggested a hyperbolic 
competitive inhibition, a point of view which is favored 
by the demonstration of a hormone receptor l antibody 
complex. The availability of the antireceptor sera con- 
firmed previous data that differential affinity chroma- 
tography separated growth hormone and prolactin re- 
ceptors in solubilized rabbit liver membrane prepara- 
tions. The antireceptor sera will be useful probes in 
further characterization of the growth hormone recep- 
tor. 
A number of aspects of receptor structure, function, and 
turnover can be probed with specific antireceptor antisera, 
and for this reason efforts have been made to generate antisera 
against a number of partially or totally purified receptor 
preparations (l-5). In some pathological states such antisera 
occur naturally as a result of an autoimmune disorder, and 
this provides a rather more convenient source of such anti- 
bodies (1,6,7). These antireceptor antisera may act as agonists 
(3, 7-9) or as antagonists (1, 4, 10) of hormone action and 
provide useful tools for studying the mechanisms of hormone- 
receptor interaction (1, 7, 10). Indeed, if these antibodies are 
generated against a purified putative receptor, their effective- 
ness in blocking hormone action in vitro can be taken as 
evidence that a receptor molecule and not a hormone-degrad- 
ing enzyme has been isolated (10,ll). Furthermore, antibodies 
raised against the individual polypeptide chains of a purified 
receptor are of great utility in defining the role of these chains 
in overall receptor function (12). 
These antibodies can also be used as structural probes to 
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study the species specificity of structural determinants on the 
receptor molecule, including those determinants not directly 
at the hormone-binding site (1, 13). Similarly, pathological 
structural variants of receptors may be detected with antire- 
ceptor antisera of defined specificity. Such antibodies are also 
valuable in electron microscopic studies of receptor distribu- 
tion (14). Immunoprecipitation of labeled, newly synthesized 
receptors with antireceptor antibodies (15) is also likely to 
provide a major use for these antibodies in the future. Finally, 
active immunization with purified receptors (1,ll) or passive 
immunization with antireceptor antibodies (16, 17) provides 
important information about the in viva role of these receptors 
and can provide useful experimental models for specific au- 
toimmune diseases such as myasthenia gravis, where divalent 
anti-acetylcholine receptor antibodies induce disappearance 
of acetylcholine receptors (18), both by “modulation” and by 
directing macrophage attack ( 1). 
We have recently developed a method for the more than 
8000-fold purification of rabbit liver growth hormone recep- 
tors by a combination of differential affinity chromatography, 
isoelectric focusing, and gel filtration (19). The work presented 
here describes the characterization of antisera generated 
against this preparation and the use of these antisera for 
structural analysis of the receptor. This study provides a 
starting point for further studies of the growth hormone 
receptor structure, function, and turnover based on the use of 
these antisera. 
MATERIALS AND METHODS 
Ovine growth hormone (NIH oGH’ 098), bovine growth hormone 
(NIH bGH 1003A), and ovine prolactin (NIH oPr1 S12) were gifts of 
the National Institutes of Health. Insulin (crystalline pork insulin, 24 
IU/mg) was donated by Connaught Laboratories, Toronto, and highly 
purified bovine follitropin was a gift from Dr. K. W. Cheng, University 
of Manitoba. All hormones except insulin were iodinated by the 
lactoperoxidase method of Thorell and Johansson (20) as described 
previously (19). Insulin was iodinated with chloramine-T, using a 2 
M excess of chloramine-T reacted for 25 s at 20°C. All hormones were 
fractionated on Sephadex (G-100 or G-50) columns after iodination. 
y-Globulin fractions (5 pg) were iodinated as described with lactoper- 
oxidase, and the resulting iodination mixture fractionated on Sepha- 
rose CLGB. 
Goat anti-guinea pig immunoglobulins was purchased from Miles 
Laboratories, Inc. Rabbit anti-human growth hormone (anti-hGH) 
and rabbit anti-ovine growth hormone (anti-oGH) antisera were 
generated against National Institutes of Health standard preparations 
in our laboratory using standard techniques. 
Preparation of Receptor-containing Fractions-The liver receptor 
preparations used in this study represent three stages in the purifi- 
cation of the growth hormone (GH) receptor, as described elsewhere 
(19). For most of the basic studies on inhibition of ““I-hormone 
binding, crude microsomal (100,000 X g/60 min) fractions of late 
pregnant rabbit, sheep, mouse, and rat livers, or of human liver, were 
used. Similar fractions were also prepared from term human placenta, 
porcine testis, and late pregnant rabbit mammary tissue for the 
’ The abbreviation used is: GH, growth hormone. Prefixes indicate 
species origin; o, ovine; b, bovine; h, human. 
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specificity studies. In all cases, initial homogenization of the tissue 
was obtained with a Polytron PT-10 homogenizer (Brinkmann) at a 
setting of 8 to 10 for 30 to 60 s, depending on the nature of the tissue. 
Protein content of the resuspended membranes was estimated by the 
method of Lowry et al. (21) using albumin standards. 
Immunoprecipitation and some inhibition studies were carried out 
in some cases with crude Triton X-100 solubilized (1% v/v) extracts 
of pregnant rabbit liver membranes (300,000 x g/90-min superna- 
tams). In other cases, rabbit liver growth hormone and prolactin 
receptors purified by differential affinity chromatography on hGH 
affinity columns (19) were used. 
Binding Assays-The membrane-binding assay was essentially 
that of Tsushima and Friesen (22) except that membranes (0.2 ml in 
25 II~M Tris-HCl, 10 mM MgC12, 0.1% albumin, pH 7.5, radioreceptor 
assay buffer) were preincubated for 16 h at 4°C with antisera dilutions 
(0.1 ml) before being washed three times with 10 volumes of assay 
buffer. Membranes were then resuspended in 0.3 ml of assay buffer, 
and the hormone-binding reaction was initiated by the addition of 
‘Z51-hormone with or without excess unlabeled hormone, in order to 
determine specific binding. An incubation time of 3 to 5 h at 22°C 
was used for GH receptor assay, an incubation of 16 h at 22°C for 
prolactin and follitropin receptors, and an incubation of 16 h at 4°C 
was used for insulin receptor assay. Incubations were terminated by 
the addition of 3 ml of ice cold assay buffer, centrifuged, decanted, 
and the pellets counted. For soluble receptor assay inhibitory serum 
effects were generally minimized by the use of y-globulin fractions, 
and bound/free separation was achieved with polyethylene glycol 
(PEG) 6000 (23). Determinations were always at least in duplicate in 
all binding assays. 
In some experiments an immunoprecipitation technique was used 
to obtain bound/free separations, and in this case the soluble recep- 
tors were prelabeled with ‘?-hormone for the standard incubation 
time in assay buffer, and the hormone.receptor complex was then 
combined with antireceptor antibody at varying dilutions over a 16-h 
4°C incubation. After addition of normal guinea pig serum to give a 
fixed final serum concentration, the ternary complex was immuno- 
precipitated by the addition of anti-guinea pig immunoglobulin anti- 
serum at the appropriate dilution.* Specific binding was determined 
by subtraction of values obtained for tubes containing excess unla- 
beled hormone, introduced before the start of the original incubation. 
In order to facilitate comparison, most of the data presented here 
have been expressed as a percentage of the specific binding value 
obtained with the control (zero antiserum), which was generally 10 to 
20% of total counts added. 
Immunization-Adult female guinea pigs were injected dorsally at 
multiple (10 to 20) intradermal sites with a variety of purified receptor 
preparations.mixed with 2 volumes of Freund’s adjuvant in a final 
volume of up to 1.5 ml. Animals were injected at 14-day intervals and 
after at least three immunizations bled at ll-day intervals by cardiac 
puncture. Four animals were immunized with lo-pg lots of highly 
purified (>8000-fold) rabbit liver GH receptors in 25 mru Tris-HCl, 
0.1% Triton X-100, pH 7.4, obtained as described previously (19).3 
Two other animals were immunized with 50-ng lots of post-GH 
affinity-purified (400-fold purified) GH receptor fraction. A number 
of other animals were immunized with a highly purified (>lOOO-fold) 
preparation of rabbit mammary prolactin receptors, as described by 
Shiu and Friesen (2). 
In all cases antisera were screened at various dilutions for inhibition 
of binding of ?-oGH or ‘251-oPrl to rabbit liver or mammary mem- 
branes as outlined previously. 
Crude y-globulin fractions were prepared from suitable antisera by 
the addition of 1 volume of saturated ammonium sulfate in 0.05 M 
sodium phosphate buffer, pH 7.4, followed by extensive dialysis of the 
twice-washed precipitate against 0.15 M NaCl in 10 mu sodium 
phosphate, pH 7.4. 
RESULTS 
Inhibitory Action of Antisera Toward oGH Binding 
Assay of a number of antisera for inhibition of ‘251-oGH 
binding to rabbit liver membranes as previously described 
’ Determined by the oGH radioimmunoassay using guinea pig anti- 
oGH. 
3 Lindstrom et al. (12) have reported experimental myasthenia 
gravis in rats with doses as low as 0.3 pg of purified acetylcholine 
receptor, in accord with the highly immunogenic nature of complex 
glycoproteins. 
gave the results shown in Fig. 1. It can be seen that antisera 
numbers 1 to 4 generated against the highly purified GH 
receptor preparation were able to effectively inhibit the bind- 
ing of ‘251-oGH, while a number of control sera, including 
antimammary prolactin receptor antisera, were without effect. 
The most effective antiserum, number 3, was inhibitory at a 
final dilution of 1:40,000 and totally blocked ‘251-oGH binding 
at a final dilution of 1:300. In general, these levels of inhibition 
were maintained for at least four bleedings after the last 
immunization. Strong inhibition was also obtained with serum 
from two guinea pigs immunized with 50-pg lots of post-hGH 
affinity-purified GH receptor (approximately 400-fold puri- 
fied), 50% inhibition being achieved at a final dilution of 1: 
25,000 of antiserum. It should be noted that a time course 
study showed that inhibition was maximal after 6 h at 22°C 
or overnight at 4”C, although most of the inhibition was 
attained within 2 h at 22°C. 
Specificity of Inhibition 
In order to establish the specificity of this inhibition, we 
examined the effects of these antisera on the binding of a 
number of other ?-labeled hormones to their receptors. Fig. 
2A shows that these antisera, as well as control sera, had no 
effect on the binding of ‘251-oPrl to late pregnant rabbit 
mammary membranes, while antisera generated against par- 
tially purified (>lOOO-fold) rabbit mammary prolactin recep- 
tors inhibited iz51-oPr1 binding effectively. In Fig. 2B ‘this 
experiment was repeated with rabbit liver membranes, and it 
can be seen that here the anti-prolactin receptor antiserum 
was not as effective in inhibiting iz51-oPr1 binding as it was 
with the mammary prolactin receptor. This is presumably 
because the growth hormone receptor comprises a component 
of the ‘251-oPrl binding, and this component can be inhibited 
by anti-GH receptor antisera as iUustrated in the figure (see 
under “Discussion”). The binding of ‘a51-insulin to rabbit liver 
and human placental membranes was unaffected by antisera 
1:4, as was the binding of ‘251-bovine follitropin to porcine 
testicular membranes (data not shown). Thus, it would seem 
that the inhibitory effect is specific for the GH receptor among 
the polypeptide hormone receptors examined. 
Inhibition of 1251-oGH binding as described could also result 
from the presence of anti-oGH or anti-hGH antibodies gen- 
erated against hGH originating from hGH affinity columns by 
release of bound hormone. The hGH becomes bound to the 
gq ;I;; ,F$p$& 
1:lO’ 1:103 1:102 AS31:lO’ 
INITIAL DILUTION OF ANTISERA 
FIG. 1. Inhibition of ‘251-oGH binding to rabbit liver membranes 
by antisera raised against purified GH receptors. The assay procedure 
is described under “Materials and Methods” and involved preincu- 
bation of pregnant liver microsomal membranes X (114 gg of protein) 
for 16 h at 4°C with varying dilutions of antisera (ASI to 4) and 
control sera, followed by buffer wash of the membranes, addition of 
‘?-oGH (76,500 cpm), and incubation for 5 h at 22°C. Excess unla- 
beled oGH (1 &ml of final concentration) was added to determine 
specific binding in zero antiserum tubes, and all data are expressed as 
a percentage relative to this control (15.3%). Normal guinea pig (G.P.) 
serum controls (3) also included antimammary prolactin receptor 
antiserum. 
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FIG. 2. A, effect of antireceptor anti- 
sera on ‘251-oPrl binding to late pregnant 
rabbit mammary membranes. Zero anti- 
serum tubes containing 205 pg of mem- 
brane protein gave 12.2% specific bind- 
ing. Assay as for Fig. 1, except for 16 h at 
22°C incubation for ?-oPr1 binding. EI, 
antimammary prolactin receptor anti- 
sera; 0, antiliver GH receptor antisera; 
A, normal guinea pig sera (2). B, effect 
of antireceptor antisera on ?-oPr1 bind- 
: 
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16 ing to late pregnant rabbit liver mem- 
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N 
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INITIAL DILUTION OF ANTISERA specific binding. Symbols are the same 
as for A. 
soluble receptors and is carried through the remainder of the 
purification procedure. This can be demonstrated by coupling 
‘251-hGH to the affinity columns along with the hGH and then 
following the counts (19). Fig. 3 shows that no anti-oGH 
antibodies are present in the four antisera and that only a 
trace of anti-hGH antibody is present in antiserum 3. In 
another experiment, incubation of ‘251-oGH with antiserum 3 
at a 1:40 dilution for the standard assay time (5 h, 22’C) 
produced no change in the elution position of ‘251-oGH (2 x 
void volume) on a Sephadex G-100 column (1.5 x 50 cm), 
indicating the absence of hormone-binding proteins in the 
antiserum. Since the membrane wash procedure prior to 
addition of ‘251-oGH reduces serum proteins to a very low 
level, it is considered extremely unlikely that the inhibition of 
‘?-oGH binding shown here results from the presence of anti- 
oGH antibodies or other serum oGH-binding proteins. 
Immunoglobulin Nature of the Inhibitory Activity 
The inhibitory activity is an immunoglobulin, according to 
the following criteria. Firstly, inhibitory activity is only pres- 
ent in the 20 to 40% ammonium sulfate fraction and elutes in 
the same position as the y-globulin standard on Sepharose 6B 
(Fig. 4). Secondly, it is possible to immunoprecipitate the lz51- 
oGH-soluble receptor complex after it has been incubated 
with antisera 1 to 4 by the addition of goat anti-guinea pig 
immunoglobulin antisera. Fig. 5A shows that only the y-glob- 
ulin fractions derived from antisera 1 to 4 were able to facili- 
tate immunoprecipitation of hormone. receptor complexes in 
soluble rabbit liver extracts. The maximum extent of ‘251-oGH 
specifically immunoprecipitated (12%, calculated as the per- 
centage of counts immunprecipitated after subtraction of the 
percentage precipitated in the presence of 1 pg/ml of oGH) 
approaches the amount of specific binding determined by 
polyethylene glycol precipitation (14%). The order of effec- 
tiveness of the antisera in immunoprecipitation also correlated 
with their effectiveness in inhibiting binding of ‘““I-oGH to 
liver membrane preparations. The specificity of the immuno- 
precipitation reaction was corroborated by the lack of immu- 
noprecipitation of lz51-oPrl a prolactin receptor complexes in 
rabbit mammary gland-soluble extracts by these antisera, 
whereas anti-prolactin receptor antisera were able to immu- 
noprecipitate all of the specifically bound ““I-oPrl (data not 
shown). Immunoprecipitation of ‘251-oGH was also observed 
when the highly (>8000-fold) purified receptor was incubated 
with y-globulin fractions from serum 3, and the extent of 
immunoprecipitation found correspond to the extent of spe- 
cific binding of. ‘““I-oGH determined by polyethylene glycol 
precipitation (5.2%) (Fig. 5B). Thus there is good evidence 
that the inhibitory activity is an antibody generated against 
the purified putative growth hormone receptor. 
TEST FOR ANTIBODIES IN ANTI-GH RECEPTOR ANTISERA 
~~‘~- 
INITIAL DILUTION OF ANTISERA 
FIG. 3. Tests for antihormone antibodies in antireceptor antisera. 
Indicated dilutions of antisera were added in 0.1 ml of 2.5% albumin, 
0.01 M sodium phosphate, 0.15 M NaCl, pH 7.4, to 0.2 ml of the same 
buffer. Then 0.1 ml of ““I-hGH (30,400 cpm) or ““I-oGH (19,400 cpm) 
was added to the tubes and a 10-h 22°C incubation commenced. This 
was followed by the addition of 0.1 ml of 1:lOO normal guinea pig 
serum and then 0.1 ml of rabbit anti-guinea pig y-globulin at 1:3 
dilution. After a further overnight 4°C incubation, the tubes were 
centrifuged, aspirated, and the pellets counted. Control tubes were 
included with normal guinea pig serum alone, with excess unlabeled 
hormone (0.1 ml, 5 pg/ml), and without the second antibody. Guinea 
pig anti-hGH antiserum was used as the positive control for hGH 
antibodies, and rabbit anti-oGH and oGH antibodies (the latter 
required the use of sheep anti-rabbit y-globulins at 1:20 for second 
antibody). W, anti-hGH antiserum; 0, anti-oGH antiserum; 0, 0, A, 
anti-GH receptor antisera 1, 2, 4; A, anti-GH receptor antiserum 3. 
O,Bc.--.-.-.-.-.--.----.. fCC’...-.- CC.-.+.-.-.-.-. jlO0 ( 
FRACTION NUMBER (2.2 ml) 
FIG. 4. Gel filtration of 0 to 33% ammonium sulfate fraction of 
antiserum 3 on Sepharose GLGB. y-Globulin fraction (0 to 33% 
(NH&SO,) corresponding to 0.6 ml of antiserum 3 (1.1 mg of protein)) 
was loaded onto a Sepharose CLGB column (1.3 X 55 cm) in 0.6 ml of 
phosphate/saline buffer and run with a 40-cm head at 2°C in phos- 
phate/saline buffer. Aliquots (0.1 ml) of 1:3 dilutions of each fraction 
were assayed for inhibitory activity in the standard liver membrane 
assay with ‘251-oGH (13.5% specific binding, 100 pg of protein). Arrow 
at peak indicates elution position of bovine y-globulin standard. Tube 
10 was used for iodination after concentration against Ficoll 4000, as 
described under “Materials and Methods.” VO, void volume; VT, bed 
volume. 
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FIG. 5. A, immunoprecipitation of ‘*“I-oGH. receptor complexes in 
soluble rabbit liver extracts by anti-GH receptor antisera. Triton X- 
lOO-solubilized rabbit liver membrane (130 pg of protein) in 0.1 ml of 
radioreceptor assay buffer was added to 0.2 ml of the same buffer and 
0.1 ml of ‘251-oGH (40,000 cpm). Tubes were included with excess 
unlabeled oGH (0.1 ml, 5 pg/ml of oGH) substituted for 0.1 ml of 
buffer. After a 5-h 22°C incubation, indicated dilutions of the various 
antisera (AS1 to 4) were added in 0.1 ml of radioreceptor assay buffer. 
This was followed by a further incubation for 24 h at 4°C before the 
addition of 0.1 ml of normal guinea pig serum to give a uniform serum 
concentration equivalent to 1:32 of initial dilution and 0.1 ml of rabbit 
anti-guinea pig antiserum at 1:lO. After another 4’C incubation for 16 
h, tubes were centrifuged and aspirated, and pellets were counted. 
Three normal sera were included as controls. A parallel experiment 
using the normal soluble receptor assay and polyethylene glycol 
separation showed that 14% of added ““I-oGH was specifically bound 
by this quantity of solubilized receptor. B, immunoprecipitation of 
highly purified GH receptors with anti-GH receptor y-globulin. GH 
receptor (to.03 pg of >8000-fold purified) was incubated with indi- 
cated dilutions of 1.8 mg/ml of y-globulins derived from antiserum 3, 
using the procedure outlined in the previous figure and 80,000 cpm of 
““I-oGH. bGH, bovine growth hormone; n , antireceptor y-globulins; 
A, normal serum y-globulins. 
Mechanism of Inhibiton 
Lineweaver-Burk analysis of the inhibition produced by 
different concentrations of the y-globulins from antiserum 3, 
in the presence of varying ““I-oGH concentrations (Fig. 6A) 
shows the mechanism of inhibition to be competitive, resulting 
in a lowered affinity of receptor for its hormone. This obser- 
vation is in apparent disagreement with the observation that 
these antibodies can form an immunoprecipitable ternary 
complex with the ‘251-oGH-soluble receptor complex. How- 
ever, a Dixon plot of the Lineweaver-Burk data (Fig. 6B), 
along the lines suggested by Shiu and Friesen (2), reveals that, 
as with the prolactin receptor antisera, the plot obtained is 
similar to that seen with hyperbolic competitive inhibition 
(24), which would allow for the existence of ‘251-hormone. 
receptor. antibody complexes. This conclusion is supported by 
the results shown in Fig. 7, which demonstrate that the order 
of addition of trace and antibody are critical in facilitating 
ternary complex formation. Thus, if the normal order of fist 
0 0.2 0.4 0.6 0.8 1.0 
1/‘2sl-oGH(nmol) 
IB ,D O.G98nM 
1:hO 1:1&i l:k2 
GAMMA GLOBULIN 
FIG. 6. A, reciprocal plot analysis of the inhibition of binding of 
““I-oGH to liver membranes by several dilutions of antibody. Tripli- 
cate tubes containing 80 pg of rabbit liver membrane were incubated 
in the presence of varying concentrations of ‘251-oGH (35.5 pCi/pg) 
and the indicated dilutions of 1.8 mg/ml of y-globulins derived from 
antiserum 3 for 5 h at 22°C. One set of tubes containing 1 pg/ml of 
oGH in place of the antiserum was also included at each level of m’I- 
oGH, as was a zero antiserum (OAB), zero unlabeled set, and a set 
with normal guinea pig serum y-globulins at the same concentration 
as the antiserum. The latter showed no inhibition of ‘““I-oGH binding. 
Extent of inhibition by antiserum was calculated relative to the excess 
unlabeled tube. Specific binding ranged for 18 to 10% with increasing 
‘?-oGH concentration. Ordinate represents bound ““I-oGH, abscissa 
added ‘*“I-oGH. B, Dixon plot of data from Fig. A, showing hyperbolic 
competitive type of inhibition. Ordinate represents bound ““I-oGH at 
the indicated concentrations of ““I-oGH. 
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INITIAL DILUTION OF ANTISERA 
FIG. 7. Effect of order of addition of ‘*“I-oGH and antisera on 
immunoprecipitation of hormone. receptor complexes. This experi- 
ment was set up exactly as described for Fig. 5, except that the order 
of addition of trace and antisera (number 3) was reversed for one set 
of tubes. 0, ““I-oGH added first; 0, antiserum added frost. 
addition of trace followed 5 h later by antibody addition is 
reversed, producing a situation closer to the membrane assay, 
immunoprecipitation of ternary complexes by second anti- 
body is markedly reduced. Thus it seems that at least one of 
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the antigenic determinants overlaps with the hormone-bind- 
ing site in such a way as to partially block it. 
Further evidence for competition by these antibodies in the 
region of the binding site was provided by an experiment with 
pg/ml GAMMA GLOBULIN STANDARD 
FIG. 8. Correspondence of displacement of specific ‘251-y-globulin 
binding and ?-oGH binding by antiserum y-globulins. y-Globulin 
fractions derived from antiserum 3 by ammonium sulfate precipitation 
and Sepharose CLGB gel filtration were lactoperoxidase-iodinated as 
described under “Materials and Methods.” Rabbit liver membranes 
(160 pg of protein) were incubated with 0.1 ml of y-globulin and 5 X 
lo5 cpm of ‘251-y-globulins (60 @i/pg) in a final volume of 0.5 ml, 
using radioreceptor assay buffer with 1% albumin added. A parallel 
set of incubations was set up with ‘T-oGH (80,000 cpm) and the same 
set of y-globulin standards. Two parallel sets of tubes were also set up 
with normal serum y-globulins. All tubes were then incubated for 6 h 
at 22”C, and the reaction was terminated by chilled buffer addition 
and centrifugation, as usual. A total binding of 2.2% was obtained 
using ‘2”I-y-globulins, and 40% of these counts were displaced by 500 
rig/ml of antireceptor y-globulin standard only. Addition of 1 pg/ml 
of oGH also displaced 25% of bound ‘?-y-globulins. A total of 14% of 
‘?-oGH added was specifically bound, and, as can be seen, displace- 
ment of the tracer by increasing concentrations of antireceptor y- 
globulins coincided with the ability of these y-globulins to displace 
‘251-y-globulin binding. n , ?-y-globulin binding, displacement by 
antireceptor y-globulins; A, ?-oGH binding, displacement by anti- 
receptor y-globulins, 0, lz51-oGH and ‘251-y-globulin binding, displace- 
ment by normal serum y-globulins. 
lz51-labeled y-globulins derived from antiserum 3, prepared by 
the techniques described under “Materials and Methods.” 
Addition of 5 X lo5 cpm of labeled y-globulin to rabbit liver 
membranes resulted in a small but consistent (approximately 
2%) amount of label bound, and a considerable proportion of 
this bound tracer could be displaced by preincubation with 
increasing concentrations of y-globulin standards (Fig. 8). 
Displacement was specific in that three normal serum y- 
globulins had no effect on ‘251-y-globulin binding, and it can 
be seen that the range of specific y-globulin concentrations 
required to obtain displacement correlates very closely with 
the concentrations needed to block lz51-oGH binding in a 
parallel experiment. This correlation is in agreement with the 
concept of competition by antibody in the region of the 
hormone-binding site. The experiment also illustrates that 
these anti-GH receptor antibodies comprise only a small per- 
centage of the total y-globulin population, as expected. Only 
a part (62%) of the y-globulin displaceable ‘251-y-globulin 
binding was displaceable by oGH (1 pg/ml). 
Structural Studies 
Species Specificity-One of the uses of antireceptor anti- 
bodies is that of a probe for structural similarities between 
receptors from different species. Currently, growth hormone 
receptors have been identified in pregnant rabbit, rat, mouse, 
and sheep livers, and in human liver (see Ref. 19). Fig. 9 shows 
the inhibition patterns obtained with the four anti-GH recep- 
tor antisera when examining ‘251-oGH, ‘251-hGH, and ‘251-oPrl 
binding to membranes prepared from these livers. It should 
be noted that control guinea pig sera were ineffective in all 
species. It is clear from this figure that while the antisera are 
considerably more effective against rabbit GH receptors than 
against the other species, nevertheless there are common 
antigenic determinants in the region of the hormone-binding 
site. The order of effectiveness of the different antisera varies 
with each species. Thus, antiserum 3 is more effective in 
rabbit and man, whereas antiserum 1 is more effective in the 
C) FEMALE SHEEP LIVER 
AS3 
1:lO’ I:ld 
INITIAL DIUJTION OF ANTMRA 
‘ii--r ~~“;; 
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FIG. 9. Effect of anti-GH receptor antisera on other species of GH branes (312 gg of protein); E, female sheep liver membranes (314 pg 
receptors. The standard membrane competitive binding assay was set of protein). In A, B, and C, ‘?-oGH was used as tracer, in D, ‘%I- 
up with varying dilutions of antisera (ASI to 4) and the following hGH, and in E, ‘251-oPl ( lz51-oPL). Approximately 80,000 cpm of 
receptors: A, pregnant rat liver membranes (710 pg of protein); B, tracer was added in all cases, and incubation was for 6 h at 22T. 
pregnant mouse liver membranes (440 pg of protein); C, female sheep Specific binding was 8.1% for A, 10.2% for B, 9.2% for C, 10.7% for D, 
liver membranes (733 pg of protein); D, female human liver mem- and 9.1% for E. 
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other species. That the inhibition of lz51-hGH binding to 
human liver was not caused by the minimal anti-hGH titer in 
antiserum 3 referred to earlier was shown by the addition of 
anti-hGH antisera at concentrations (1:104 to 2:104) able to 
totally immunoprecipitate lz51-hGH in the hGH radioimmu- 
noassay, in place of the anti-GH receptor antiserum. Subse- 
quent washing of the membranes (as detailed under “Mate- 
rials and Methods”) prior to addition of tracer resulted in no 
inhibition of lz51-hGH binding to the human liver membranes. 
Since the titer of anti-hGH antibodies found in antiserum 3 
represents only a minute portion of the anti-hGH antisera 
added here, it is extremely unlikely that the inhibition seen 
here is the result of anti-hGH antibody action. 
One other relevant finding shown in Fig. 9 is the immuno- 
logical similarity that exists between ovine placental lactogen 
and ovine growth hormone receptors in the sheep liver. Since 
there was no inhibition of ‘251-oPl binding by anti-prolactin 
receptor antisera, even though these antisera have been shown 
to be effective in species as disparate as mouse and man (2), 
it appears that the oP1 receptor closely resemblesjor is) the 
GH receptor, as indicated by hormonal specificity studies (25). 
The Shared Growth Hormone Receptor-The Scatchard 
041 
1:lO’ 1:lOJ 1:lOZ 1:lO’ 
GAMMA GLOBULIN DILUTION 
(INITIAL ANTISERUM DILUTION EQUIVALENTS) 
FIG. 10. A, effect of antireceptor y-globulins on I*?-oGH and lz51- 
oPr1 binding to GH receptor (urea) fraction purified by afbnity 
chromatography; An aliquot (5 fig of protein) of dialyzed urea fraction 
(prepared as previously described) was incubated with increasing 
dilutions of y-globulins (1.8 mg/ml) derived from anti-GH receptor 3, 
from anti-prolactin receptor antiserum, or from normal guinea pig 
serum, for 24 h at 4°C in a final volume of 0.3 ml of radioreceptor 
assay buffer. “?-oGH (66,000 cpm) or ‘251-oPrl (92,000 cpm) were 
then added, and the incubation carried on for a further 5 h at 22°C. 
The reaction was terminated with polyethylene glycol separation of 
bound and free. Triplicate tubes were included with excess cold oGH 
(1 ag/ml) for the determination of specific binding, which was 6.0% 
for ‘=I-oGH and 2.5% for ‘*‘I-oPr1. The inset figure shows the effect 
of these y-globulins on ‘251-oPrl binding. 0, anti-GH receptor y-glob- 
ulins; n , anti-prolactin receptor y-globulins; A, normal guinea pig 
serum y-globulins. B, effect of antireceptor y-globulins on ‘251-oPrl 
binding to the rabbit liver prolactin receptor (MgCL) fraction purified 
by affinity chromatography. Conditions are identical with A, except 
that only ‘251-oPrl was used, and the incubation time was 12 h at 
22°C. Specific binding of the control was 7.0%. Excess cold oPr1, 1 g/ 
ml. 
analyses and displacement data presented elsewhere (19) pro- 
vide strong support for the concept that rabbit liver contains 
a prolactin-specific receptor and a GH receptor which has a 
high affinity for oGH and lo-fold lower affinity for oPr1. 
Evidence was presented that differential affinity chromatog- 
raphy on hGH affinity gels separated these two receptors, 
specifically by means of 4 M urea elution (yielding the GH 
receptor) or 5 M MgCL elution (yielding the prolactin recep- 
tor) . 
Fig. 10, A and B, shows how we have been able to apply the 
anti-GH and anti-prolactin receptor antisera to test our hy- 
pothesis of a shared GH receptor and a specific prolactin 
receptor. Various concentrations of y-globulins of the most 
inhibitory antiserum were preincubated with the urea affinity 
fraction for 24 h at 4°C before adding lz51-oGH and performing 
the standard soluble receptor assay. Fig. 1OA shows that this 
antiserum was very effective in inhibiting lz51-oGH binding to 
the receptor and that both mammary prolactin receptor-spe- 
cific antiserum y-globulins and normal serum y-globulins were 
ineffective in competing for 12?-oGH binding. In accord with 
our hypothesis, ‘251-oPrl binding to the urea affinity fraction 
was also blocked by anti-GH receptor, but not by anti-prolac- 
tin receptor antisera y-globulins. 
When the MgClz affinity fraction (“prolactin receptor”) was 
assayed on the other hand, the anti-GH receptor antiserum 
y-globulins and normal serum y-globulins failed to inhibit 
binding of 1251-oPrl to the receptor, whereas anti-prolactin 
receptor y-globulins were very effective inhibitors (Fig. lOB), 
as would be predicted if this were a prolactin-specific receptor. 
DISCUSSION 
Evidence has been presented here that we have produced 
specific antisera to the GH receptor by immunization of guinea 
pigs with a highly purified GH-binding fraction from rabbit 
livers. The fact that these antisera did not inhibit the binding 
of ‘251-insulin or ‘251-oPrl to their respective receptors is taken 
as evidence that the affinity chromatography step has selec- 
tively separated the putative GH receptor from other poly- 
peptide hormone receptors in the solubhxed membrane ex- 
tracts. This complements the finding that anti-prolactin re- 
ceptor antisera inhibit only the binding of 1251-oPrl to its 
specific receptor and underlines the distinction between the 
two receptors. Tsushima (26) has recently presented a prelim- 
inary report on “anti-GH receptor antibodies” generated 
against a rabbit liver preparation purified by concanavalin A- 
Sepharose, DEAE-cellulose, and Sepharose 6B chromatogra- 
phy. No specificity studies were presented with this report, 
but in the light of the considerations detailed in the preceding 
paper, a hormone-specific affinity step would seem to be an 
essential prerequisite for the isolation of particular hormone 
receptor. 
We are fortunate that our antisera allowed us to test the 
hypothesis proposed on the basis of our hormone specificity 
studies in rabbit liver membranes that the liver GH receptor 
will bind oPr1, albeit with considerably lower affinity than 
oGH. Thus the anti-GH receptor antisera was able to inhibit 
both lz51-oGH and ‘251-oPrl binding to the GH receptor frac- 
tion, even though it was unable to inhibit ‘251-oPrl binding to 
the oPrl-specific receptor. Conversely, anti-prolactin receptor 
antiserum was unable to inhibit the binding of either ‘251-oGH 
or ‘251-oPrl to the GH receptor fraction. This clear immuno- 
logical separation of receptor type was only made possible by 
the use of a receptor-specific differential affinity chromatog- 
raphy procedure. 
The data presented here also represent the first demonstra- 
tion of antigenic similarities between the GH receptors of such 
differing species as mouse and man and represent the converse 
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6832 Studies with Anti-Growth Hormone Receptor Antibodies 
of studies on immunological specificity among the growth 
hormones. It is of interest that the extensive immunological 
differences between primate and nonprimate GH (27) are not 
reflected in the actions of antiserum 3, which is quite effective 
against human and rabbit liver receptors. The variability in 
relative potency of the four antisera among the five species is 
reminiscent of that reported by Flier et al. (6) for the insulin 
receptor, although it is clear that these antisera are far more 
effective against rabbit receptors. An identity of antigenic 
determinants over a wide range of species has already been 
reported for the acetylcholine receptor (1) and the prolactin 
receptor (2) and presumably indicates the importance of these 
structures (either protein or carbohydrate) in the biological 
functioning of these receptors. We intend to pursue this prob- 
lem further using the immunoprecipitative technique to ex- 
amine antigenic determinants located away from the hor- 
mone-binding site. 
The mechanistic studies reported here show that antiserum 
3 acts by decreasing the affinity of the receptor for its hor- 
mone, as do a number of other antireceptor antisera (2, 6, 7). 
The observation that it is possible to immunoprecipitate a 
ternary (hormone receptor. antibody) complex if the receptor 
is prelabeled with lZ51-oGH can be rationalized with this 
conclusion by the finding of hyperbolic competitive inhibition 
on replotting of the reciprocal plot data in the form of a Dixon 
plot. In this model the antibody would bind at a site partly 
overlapping the hormone-binding site, or it may induce a 
conformational change by binding to a distant antigenic site 
in such a way as to block hormone binding. If  the hormone 
were to bind first, this would lock the hormone receptor 
together in a way that still allowed antibody binding. The 
alternative model, involving a heterogenous population of 
antibodies directed at other antigenic sites on the receptor in 
addition to the hormone-binding site, rather like the variabil- 
ity seen with acetylcholine receptor antibodies (1) and anti- 
(Na+,K+)-ATPase antibodies (28) is also very likely. In this 
model, binding of hormone to receptor would block access of 
the binding site-directed antibodies while still allowing other 
site-directed antibodies to interact in the immunoprecipitation 
mechanism. This would explain the fact that oGH is only 
partly effective in displacing ‘““I-labeled antireceptor y-glob- 
ulins from liver membranes compared to the y-globulins them- 
selves. 
In view of the lack of homogeneity of the receptor prepa- 
ration used for immunization (one major and two minor bands 
observed on sodium dodecyl sulfate gels), it is likely that these 
antisera contain antibodies directed against some nonreceptor 
determinants. It may be possible to remove these antibodies 
by absorption with nonreceptor-containing tissues, and this 
will be necessary before these antisera can be used to study 
receptor biosynthesis. It appears unlikely that the antibodies 
studied here are directed against a molecule closely associated 
with, but different from the receptor, for two reasons. Firstly, 
the antibodies were effective in totally immunoprecipitating 
a highly (>8000-fold) purified receptor preparation, as judged 
by comparison with polyethylene glycol-determined specific 
“‘I-oGH binding. Secondly, the correlation of ‘““I-y-globulin 
displacement with ““I-oGH displacement argues in favor of a 
receptor-directed antibody, as does the finding of competitive 
inhibition and lowered receptor affinity for its hormone. 
As outlined in the introduction, there are a variety of 
valuable applications for these antibodies. At present we are 
examining the biological effects of these antisera both in vitro 
and in uiuo, with the intention of establishing the biological 
significance of the GH binding fraction and of obtaining an 
estimate of “spare receptor” content. 
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